News & Updates

Original New Drug Application Approvals by US FDA (01-15 November 2023)

New drug applications approved by US FDA as of 01-15 November  2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Add-on vancomycin of little help for surgical prophylaxis in arthroplasty

Adding vancomycin to cefazolin does not appear to confer significant benefits for the prevention of surgical site infections following arthroplasty in patients without known methicillin-resistant Staphylococcus aureus (MRSA) colonization, according to the results of the ASAP trial.

Simvastatin not superior to standard of care critically ill patients with COVID-19

In the treatment of critically ill patients with COVID-19, simvastatin is not necessarily better than standard of care in terms of improving organ support-free days and death outcomes, according to a study.

A closer look at ceftazidime-avibactam in real-world settings

Antibiotic misuse and overuse fuel mutations in bacteria, leading to drug-resistant “superbugs,” with terrifying aftermath. Without intervention, antimicrobial resistance could cause 10 million deaths annually by 2050.

Every year, from November 18–24, the World Antimicrobial Awareness Week highlights these risks and promotes innovative treatments, enhanced surveillance, and best-practice sharing among clinicians. This article offers insights on the use of the fixed-dose combination antibiotic ceftazidime-avibactam in daily hospital settings.